The Moderna Inc (NASDAQ: MRNA) share price went like gangbusters yesterday, overnight Aussie time. The US biotech company’s share price leapt 10.8%. And its up another 3.8% in afterhours trading.
This comes as investors eagerly anticipate the outcome of the final analysis of Moderna’s promising COVID-19 vaccine trial.
Earlier this month, Moderna joined Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) in a globally exclusive club when the company announced its vaccine looked to be 95% effective in its extensive trial. One which encompassed 30,000 people.
Moderna’s share price is now up 62% so far in November, and 468% so far in 2020. At the current share price, Moderna has a market cap of $48 billion.
What does Moderna do?
Based in the United States city of Cambridge, Massachusetts, Moderna is a biotechnology company. The company focuses on developing and discovering new drugs and vaccine technologies based on messenger RNA. Moderna’s technology platform inserts synthetic mRNA into human cells.
Why did the Moderna’s share price leap 11% overnight?
Moderna’s share price has been steadily moving higher on a series of positive announcements from the company.
Among those, the US has committed to buying 100 million doses of its vaccine, mRNA-1273, provided it wins emergency use approval. And it’s not just the US.
Japan has agreed to buy 50 million doses, Canada wants 20 million and, in the latest development, the European Commission agreed to buy 80 million doses with an option to double that to 160 million. That agreement remains subject to European approval of the vaccine.
The 10.8% share price leap overnight comes as Moderna expects to release the final data from its expansive trial within the next week. Should the vaccine’s efficacy prove to be in the 94.5% range as initially reported, Moderna will then file for emergency use authorisation with the US Food and Drug Administration (FDA).
If it gains approval, Moderna’s vaccine could begin mass distribution just as global infection rates are rocketing to new levels. Hence the big share price surge.
Share markets are said to be forward looking. Meaning they anticipate tomorrow’s news today.
With more than 588,000 new infections reported on Tuesday, 24 March, and global cases exceeding 60.2 million with 1.4 million fatalities, let’s all hope the market’s got this one right!
Our TOP healthcare stock is trading at a 30% discount to its highs
If there’s one thing for sure, 2020 has been the year we embraced sanitisation. Scott Phillips has discovered a little-known Australian healthcare company could be set to reap the rewards of the post-covid world.
Better yet, this fast-growing company is currently trading at a 30% discount from its highs. Scott believes in this stock so much, he’s staked $209k of our own company money on it. Forget ‘buy now pay later’, this stock could be the next hot stock on the ASX.
Scott and his team have published a detailed report on this tiny ASX stock. Find out how you can access our TOP healthcare stock today!
Find out the name of this stock
As of 2.11.2020
More reading
- Here are the US shares that CommSec customers are buying
- ASX energy shares surge ahead as oil rises to 9-month high
- Here’s why Moderna’s coronavirus vaccine could outsell Pfizer’s
- New data shows higher efficacy rate for Pfizer and BioNTech coronavirus vaccine candidate
- Here are the US shares that CommSec customers are buying
Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post With the Moderna share price blasting up, have the forward-looking markets got it right? appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/366Z8mD
Leave a Reply